IP Library Granted Patent US 9,371,373
Granted Patent B2
US 9,371,373 · App. 14/095,365 · Granted Jun 21, 2016

Monomeric VHH domain derived from anti-VP6 camelid antibodies, dimeric domain, immunisation method, composition, and treatment methods for rotavirus infections

Inventors: Thomas Surrey (Heidelberg, DE); Aurelien Olichon (Wiesenbach, DE); Lorena Laura Garaicoeachea (Ciudad de Buenos Aires, AR); Gisela Ariana Marcoppido (Ciudad de Buenos Aires, AR); Gladys Viviana Parreño (Ciudad de Buenos Aires, AR); Silvia Gómez Sebastián (Madrid, ES); José Angel Martínez Escribano (Madrid, ES); Andrés Wigdorovitz (Buenos Aires, AR)
Assignee: INSTITUTO NACIONAL DE TECHNOLOGIA AGROPECUARIA (INTA)
C07K16/10G01N33/56983A61K2039/505C07K2317/22C07K2317/31C07K2317/76G01N2333/14G01N2469/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,371,373
App. No.
14/095,365
Granted
Jun 21, 2016
Kind
B2
Abstract

Monomeric VHH domain derived from anti-VP6 camelid antibodies, dimeric domain, immunization method, and treatment method for rotavirus infections, wherein said domain may be any of the amino acid sequences shown in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, and wherein said domains bind to protein VP6 of Group A rotavirus.

Claims (14)

1. A dimeric or monomeric VHH domain characterized in that said domain comprises at least one sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.

2. The domain according to claim 1 , wherein the domain derives from antibodies of camelids selected from the group consisting of: Lama glama, Lama pacos, Lama guanicoe and Vicugna vicugna.

3. The domain according to claim 1 , wherein the domain binds to a linear epitope of the VP6 antigen present in group A of rotavirus.

4. The domain according to claim 1 , comprising two sequences, either identical or different, selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.

5. The domain according to claim 4 , wherein the domain further comprises a linkage of SEQ ID NO: 13.

6. The domain according to claim 4 , further comprising a sequence selected from the group consisting of: SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.

7. A rotavirus immunodetection method, said method comprising: a) contacting a rotavirus-containing sample with an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof; and b) detecting the rotavirus.

8. The method in accordance with claim 7 , wherein said detecting is carried out using a technique selected from the group consisting of: immunocapture based tests ELISA, ELISPOT, competition ELISA, magnetic beads, and any other chromatographic immunoassay technology.

9. A composition designed to confer passive immunity to a mammal, the composition comprising: an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof; excipients; and immunomodulators.

10. An antibody comprising any of the domains of claim 1 .

11. A kit for immunodetection of rotavirus comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof.

12. A method for treating infections produced by rotavirus, said method comprising administering an effective quantity of an amino acid sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:3, and combinations thereof, to a mammal that needs it.

13. The method of claim 12 , wherein administering comprises a route selected from the group consisting of oral, intragastric, intravenous, and intraperitoneal routes.

14. The method of claim 12 , wherein the mammal is selected from the group consisting of human beings, bovines, caprines, ovines, swines, and equines.

Priority Claims (1)
AR P070103331 · Jul 27, 2007 · national
Continuity (2)
Continuation 12670409
Related Publication 20140178405A1 · Jun 26, 2014